Quinine Sulfate Tablets

Anti-Malarial · Film-Coated Tablets · 300mg / 500mg

Trade Information

Minimum Order Qty	1,000,000 tablets
Capacity	100 Million Tablets per month
Strength	300mg / 500mg
Private Labelling	Custom branding, artwork & market-specific labelling
Lead Time	45–60 days from order confirmation
Payment Terms	LC at sight, TT (advance / against documents)
Shipping	FOB / CIF to major international ports including Mombasa, Dar es Salaam, Lagos, Durban, Manila, Phnom Penh
Pharmacopoeia	BP, USP, IP compliant

Packing Options

Blister (Alu-Alu / Alu-PVC)
Strip pack
Bottle pack (HDPE)
Hospital bulk pack
Custom packing as per buyer requirement

Regulatory & Quality

Registration Status	Registered in multiple African and Asian markets. Dossier available for new market registration.
Regulatory Dossiers	CTD / ACTD format dossiers available for submission to national drug authorities.
Stability Data	Zone IVa & IVb stability data available (tropical climate conditions, 30°C/65% RH & 30°C/75% RH)
WHO Prequalification	WHO-GMP Certified

Product Details

Composition	Quinine Sulfate
Dosage Form	Film-Coated Tablets
Pack Size	10x10, Bottle of 100/500/1000 / Custom packing available
Storage	Store below 30°C in a dry place, protected from light
Shelf Life	36 months from date of manufacture

Description

Quinine Sulfate is one of the oldest and most established antimalarial drugs, derived from the bark of the cinchona tree. It remains a critical treatment option for chloroquine-resistant P. falciparum malaria and is listed on the WHO Model List of Essential Medicines.

Quinine is particularly important in the management of severe and complicated malaria where ACTs may not be available or suitable. It is also used as a second-line treatment and for malaria in pregnancy (second and third trimesters).

BioGalen manufactures Quinine Sulfate Tablets in 300mg and 500mg strengths. Our products are widely supplied to malaria-endemic countries across Sub-Saharan Africa and Southeast Asia through government tender programmes and private distribution channels.

Mechanism of Action

Quinine is a cinchona alkaloid that accumulates in the acidic food vacuole of the Plasmodium parasite. Inside the vacuole, the parasite digests host haemoglobin, releasing toxic free heme as a byproduct. The parasite normally detoxifies heme by polymerising it into insoluble hemozoin (malaria pigment). Quinine inhibits this heme polymerisation process, causing a buildup of toxic free heme that damages parasite membranes and leads to parasite death. Quinine also intercalates into parasite DNA and may interfere with protein synthesis. Unlike artemisinins, which act rapidly but are cleared quickly, Quinine has a longer duration of action (half-life 10–12 hours) and remains effective against chloroquine-resistant P. falciparum strains, making it a critical second-line and rescue therapy.

Indications

Treatment of uncomplicated P. falciparum malaria (where ACTs are unavailable)
Treatment of severe and complicated malaria (oral follow-up therapy)
Chloroquine-resistant malaria
Malaria in pregnancy (second and third trimesters)
Nocturnal leg cramps (off-label use)

Available Variants

Quinine Sulfate Tablets 300mg
Quinine Sulfate Tablets 500mg

Frequently Asked Questions

When is Quinine preferred over ACTs for malaria treatment?

Quinine remains the treatment of choice in several scenarios: severe malaria (oral follow-up after injectable treatment), first-trimester malaria in pregnancy (where ACTs are not recommended), treatment failure with ACTs, and in facilities or regions where ACTs are out of stock. It is a critical essential medicine that every malaria-endemic health system must maintain in its supply chain.

Why does BioGalen offer both 300mg and 500mg strengths?

Prescribing practices vary by region. The 300mg strength is standard in Francophone African markets (total daily dose of 1800mg as 300mg x 3 doses x 2 tablets), while the 500mg strength is preferred in Anglophone markets and Southeast Asia (1500mg daily as 500mg x 3). Offering both strengths allows distributors to match local prescribing conventions exactly.

What is the typical procurement volume for Quinine in malaria-endemic countries?

Quinine is procured in significant volumes by government health ministries as a strategic reserve and second-line treatment. While ACTs dominate first-line procurement, Quinine is essential for hospital formularies and severe malaria management. Annual national procurement can range from 5–50 million tablets depending on country size and malaria burden.

Are injectable Quinine formulations also available?

BioGalen currently offers Quinine in oral tablet form (300mg and 500mg). For injectable malaria treatment, we manufacture Artesunate Injection (60mg, 120mg, 180mg) which is the WHO-recommended first-line treatment for severe malaria. Contact us for our complete antimalarial portfolio.

Interested in Quinine Sulfate Tablets?

Get competitive pricing for bulk orders, private labelling, and contract manufacturing.

WhatsApp Enquiry Contact Us

Browse Categories

Browse by Dosage Form